To accelerate growth both organically and through corporate development activities
Dublin-based pharmaceutical company Endo International is making a number of changes to its executive leadership and senior management team to support its aim of becoming a leading global speciality healthcare company and accelerate growth both organically and through corporate development activities.
Under the new management structure, Endo's US Branded Pharmaceuticals and US Generics business units, as well as the company's Branded Pharmaceutical R&D, will report directly to Rajiv De Silva, President and CEO of Endo.
With the proposed new structure, Don DeGolyer, Chief Operating Officer, Pharmaceuticals has decided to leave the company. He will step down on 1 March, 2015 and remain with the company until 1 August in the capacity of a special advisor to the CEO.
After the completion of Endo's US$2.6bn acquisition of Auxilium Pharmaceuticals, expected early this year, the company's US Branded Pharmaceuticals business will continue to be led by Brian Lortie as President.
Additionally, Blaine Davis will become Senior Vice President and General Manager of the newly created speciality pharmaceuticals business unit, reporting to Lortie. Davis was previously President of Endo Ventures and Senior Vice President of Corporate Affairs.
The company anticipates defining subsequent senior leadership roles within the US Branded Pharmaceuticals business prior to the acquisition completion.
Beginning on 1 March, Robert Rush, currently Endo's Senior Vice President, Finance, will assume the newly created role of General Manager, Qualitest on an interim basis while the company conducts a search for a permanent appointee.
Susan Hall, Endo's current Chief Scientific Officer and Global Head of Research and Development and Quality will continue in this role.
The company anticipates defining additional senior leadership roles within the Branded Pharmaceutical R&D organisation given the expanded portfolio of development assets.
After the close of the Auxilium transaction, Keri Mattox, Auxilium's current Senior Vice President of Investor Relations and Corporate Communications, will become Senior Vice President of Investor Relations and Corporate Affairs reporting to Suky Upadhyay, Endo's EVP and Chief Financial Officer.Robert Cobuzzi will become President, Endo Ventures, located in Dublin, Ireland. He is currently Senior Vice President, R&D Strategy and Operations of Endo.